Juvenile idiopathic arthritis

An update on current pharmacotherapy and future perspectives

Dawn M. Wahezi, Norman Todd Ilowite

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. Therapeutic advances in the treatment of JIA are occurring at a rapid rate, resulting in more ambitious therapeutic goals and increasing numbers of children experiencing complete clinical remission. Areas covered: The purpose of this review is to summarize the available treatments for the management of arthritis and systemic features in children with JIA, including current evidence supporting the safety and efficacy of biologic agents and future therapeutic approaches. Expert opinion: With advances in pharmacotherapy, physical and functional outcomes in children with JIA have improved immensely. The establishment of research consortia among the pediatric rheumatology community has allowed for large controlled studies and enabled a better understanding of the safety and efficacy of these therapeutic agents in children. Long-term safety data remain limited and thus longer, larger safety studies are warranted.

Original languageEnglish (US)
Pages (from-to)975-989
Number of pages15
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number8
DOIs
StatePublished - Jun 2013

Fingerprint

Juvenile Arthritis
Drug Therapy
Safety
Therapeutics
Expert Testimony
Biological Factors
Rheumatology
Rheumatic Diseases
Arthritis
Chronic Disease
Pediatrics
Research

Keywords

  • Biologics
  • Juvenile idiopathic arthritis
  • Pediatric rheumatology
  • Treatment

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Juvenile idiopathic arthritis : An update on current pharmacotherapy and future perspectives. / Wahezi, Dawn M.; Ilowite, Norman Todd.

In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 8, 06.2013, p. 975-989.

Research output: Contribution to journalArticle

@article{9b4d8850405a43b1abffdd0a126cbed1,
title = "Juvenile idiopathic arthritis: An update on current pharmacotherapy and future perspectives",
abstract = "Introduction: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. Therapeutic advances in the treatment of JIA are occurring at a rapid rate, resulting in more ambitious therapeutic goals and increasing numbers of children experiencing complete clinical remission. Areas covered: The purpose of this review is to summarize the available treatments for the management of arthritis and systemic features in children with JIA, including current evidence supporting the safety and efficacy of biologic agents and future therapeutic approaches. Expert opinion: With advances in pharmacotherapy, physical and functional outcomes in children with JIA have improved immensely. The establishment of research consortia among the pediatric rheumatology community has allowed for large controlled studies and enabled a better understanding of the safety and efficacy of these therapeutic agents in children. Long-term safety data remain limited and thus longer, larger safety studies are warranted.",
keywords = "Biologics, Juvenile idiopathic arthritis, Pediatric rheumatology, Treatment",
author = "Wahezi, {Dawn M.} and Ilowite, {Norman Todd}",
year = "2013",
month = "6",
doi = "10.1517/14656566.2013.783569",
language = "English (US)",
volume = "14",
pages = "975--989",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Juvenile idiopathic arthritis

T2 - An update on current pharmacotherapy and future perspectives

AU - Wahezi, Dawn M.

AU - Ilowite, Norman Todd

PY - 2013/6

Y1 - 2013/6

N2 - Introduction: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. Therapeutic advances in the treatment of JIA are occurring at a rapid rate, resulting in more ambitious therapeutic goals and increasing numbers of children experiencing complete clinical remission. Areas covered: The purpose of this review is to summarize the available treatments for the management of arthritis and systemic features in children with JIA, including current evidence supporting the safety and efficacy of biologic agents and future therapeutic approaches. Expert opinion: With advances in pharmacotherapy, physical and functional outcomes in children with JIA have improved immensely. The establishment of research consortia among the pediatric rheumatology community has allowed for large controlled studies and enabled a better understanding of the safety and efficacy of these therapeutic agents in children. Long-term safety data remain limited and thus longer, larger safety studies are warranted.

AB - Introduction: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. Therapeutic advances in the treatment of JIA are occurring at a rapid rate, resulting in more ambitious therapeutic goals and increasing numbers of children experiencing complete clinical remission. Areas covered: The purpose of this review is to summarize the available treatments for the management of arthritis and systemic features in children with JIA, including current evidence supporting the safety and efficacy of biologic agents and future therapeutic approaches. Expert opinion: With advances in pharmacotherapy, physical and functional outcomes in children with JIA have improved immensely. The establishment of research consortia among the pediatric rheumatology community has allowed for large controlled studies and enabled a better understanding of the safety and efficacy of these therapeutic agents in children. Long-term safety data remain limited and thus longer, larger safety studies are warranted.

KW - Biologics

KW - Juvenile idiopathic arthritis

KW - Pediatric rheumatology

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84877649341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877649341&partnerID=8YFLogxK

U2 - 10.1517/14656566.2013.783569

DO - 10.1517/14656566.2013.783569

M3 - Article

VL - 14

SP - 975

EP - 989

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 8

ER -